Claims
- 1. A prostaglandin analogue of the general formula: ##STR189## (wherein .circle.A represents a group of the general formula ##STR190## (wherein X represents a cis-vinylene group or an ethylene group, Y represents an ethylene group or a trans-vinylene group, R.sup.1 represents a hydrogen atom or a straight- or branched-chain alkyl group of 1 to 4 carbon atoms, .circle.B represents a group of the general formula: ##STR191## (wherein R.sup.2 represents a straight- or branched-chain alkyl group of 1 to 8 carbon atoms), n represents zero, or an integer of 1 or 2 and the double bond between C.sub.13 and C.sub.14 in formula (I) is E, or a non-toxic salt thereof when R.sup.1 represents a hydrogen atom, or a cyclodextrin clathrate thereof.
- 2. A prostaglandin analogue according to claim 1, wherein .circle.A represents a group of the formula (IIc), (IIe) or (IIf).
- 3. A prostaglandin analogue according to claim 2, wherein .circle.A represents a group of the formula (IIe).
- 4. A prostaglandin analogue according to claim 1, wherein R.sup.1 represents a hydrogen atom or a methyl group.
- 5. A prostaglandin analogue according to claim 1, wherein .circle.B represents a group of the formula (IIIc), (IIId), (IIIe) or (IIIf).
- 6. A prostaglandin analogue according to claim 5, wherein .circle.B represents a group of the formula (IIId) or (IIIf).
- 7. A prostaglandin analogue according to claim 1, wherein the alkyl group represented by R.sup.2, in the group of the formula .circle.B , represents a straight- or branched-chain alkyl group of 1 to 4 carbon atoms.
- 8. A prostaglandin analogue according to claim 1, wherein n represents zero.
- 9. A prostaglandin analogue according to claim 1, which is one of the general formula: ##STR192## (wherein .circle.A.sub.1 represents a group of the general formula: ##STR193## (wherein X represents a cis-vinylene group or an ethylene group, Y represents an ethylene group or a trans-vinylene group and R.sup.1 represents a hydrogen atom or a straight- or branched-chain alkyl group of 1 to 4 carbon atoms), .circle.B.sub.1 represents a group of the general formula: ##STR194## (wherein R.sup.2a represents a straight- or branched-chain alkyl group of 1 to 4 carbon atoms and n represents zero, 1 or 2), or non-toxic salt thereof, or cyclodextrin clathrate thereof.
- 10. A prostaglandin analogue which is 15-[(1S,3R)-3-propylcyclopentyl]-16,17,18,19,20-pentanor-PGF.sub.2.alpha. or methyl ester thereof.
- 11. A prostaglandin analogue according to claim 1, which is one of the general formula: ##STR195## wherein .circle.A.sub.2 represents a group of the general formula: ##STR196## (wherein X and Y are as hereinbefore defined, and R.sup.1a represents a hydrogen atom or a methyl group), and .circle.B.sub.2 represents a group of the general formula: ##STR197## (wherein R.sup.2a represents a straight- or branched-chain alkyl group of 1 to 4 carbon atoms), or non-toxic salt thereof, or cyclodextrin clathrate thereof.
- 12. A prostaglandin analogue according to claim 11, which is 15-[(1S,3R)-3-propylcyclopentyl]-16,17,18,19,20-pentanor-6-keto-PGE.sub.1 or methyl ester thereof.
- 13. A prostaglandin analogue according to claim 11, which is 15-[(1S,3R)-3-butylcyclopentyl]-16,17,18,19,20-pentanor-6-keto-PGE.sub.1 or methyl ester thereof.
- 14. A pharmaceutical composition useful in combating hypertension or inhibiting blood platelet aggregation in a patient which composition comprises as active ingredient an effective amount of at least one prostaglandin analogue of the general formula (I) depicted in claim 1, wherein the various symbols are as defined in claim 1, or a non-toxic salt thereof, or a cyclodextrin clathrate thereof, in association with a pharmaceutical carrier or coating.
- 15. A method of combating hypertension or of inhibiting blood platelet aggregation in a patient which comprises administering to the patient an effective amount of a prostaglandin analogue of the general formula (I) depicted in claim 1, wherein the various symbols are as defined in claim 1, or a non-toxic salt thereof, or a cyclodextrin clathrate thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
59-151369 |
Jul 1984 |
JPX |
|
Parent Case Info
This application is a continuation of application Ser. No. 757,305, filed July 22, 1985, now abandoned.
US Referenced Citations (5)
Foreign Referenced Citations (5)
Number |
Date |
Country |
0013955 |
Aug 1980 |
EPX |
0034778 |
Sep 1981 |
EPX |
0122019 |
Oct 1984 |
EPX |
2381043 |
Feb 1978 |
FRX |
2017699 |
Oct 1979 |
GBX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
757305 |
Jul 1985 |
|